A peer-level look at how pediatricians identify developmental concerns, fit formal screening into well-child visits, respond to parent hesitation, manage long specialist waits, recognize early autism signals, and keep children moving toward intervention while capacity remains constrained.
Audience: Pediatricians
Countries: 6
Completion Rate: 73.6%
SGID: 8943296
-Hero findings
– Quick Read — Key Findings
Pediatricians are asked to notice developmental change early, use standardized screening at defined well-child visits, discuss concerns with families, arrange evaluation, and connect children to intervention. The clinical logic is clear. The operational sequence is not always simple.
Current U.S. AAP and CDC guidance recommends developmental surveillance throughout health supervision, standardized screening at 9, 18, and 30 months, autism-specific screening at 18 and 24 months, and starting intervention for an identified delay without waiting for an autism diagnosis. The MDForLives data sits inside that handoff: concerns surface most often at 12 to 18 months, yet screening competes with limited visit time, some families prefer to wait, and specialist access can stretch well past recognition, leaving the question every team knows, how do you keep the child moving when the referral pathway is slower than the developmental clock?
59.2% say they most commonly identify, or receive initial parental concerns about, suspected speech, motor, or social delays at 12–18 months.
The 12 to 18 month peak sits far ahead of 19 to 24 months (20.4%), under 12 months (12.2%), and later ages, landing squarely in the window where developmental and autism screening is already expected. That is encouraging, but it shifts the real test downstream: when concern is recognized this early yet referral waits run for months, the interim pathway becomes part of early intervention itself rather than a preamble to it.
41.4% select ASQ-3 / ASQ-SE-2 as the tool they routinely use for developmental tracking, while 41.2% identify insufficient consultation time as the single greatest barrier to universal screening.
ASQ-3/ASQ-SE-2 leads tool use at 41.4% with M-CHAT-R/F close at 33.3%, so autism screening is already woven into the developmental workflow rather than the tools being interchangeable. The barrier side is the real story: insufficient visit time leads at 41.2%, ahead of reimbursement (20.6%), competing acute issues (17.5%), language barriers (13.4%), and scoring or EHR staffing (7.2%), so a practice can own the right instrument and still fail on the clock, which points the fix toward pre-visit completion, team scoring, and protected time, not another screen.
39.6% identify a “wait-and-see” mindset as the most common reason parents hesitate or resist developmental screening or formal evaluation.
Fear of labeling or stigma follows at 31.3% and family members downplaying symptoms at 19.8%, while distrust of screening (5.2%) and therapy-cost anxiety (4.2%) are minor. That reframes the conversation: the task is rarely convincing a family the screen is valid, but helping them see that early evaluation does not prematurely define the child’s future, and that support can begin before every diagnostic question is settled.
27.1% report typical specialist waits of 4–6 months, while 25.0% report waits longer than 12 months.
30.2% say absence of joint attention is the early ASD sign most often overlooked during primary-care screening, narrowly ahead of atypical or inconsistent eye contact at 28.1%.
The most-overlooked signs are tightly bunched: absent joint attention (30.2%) and atypical eye contact (28.1%) lead, with speech regression (18.8%) and atypical sensory responses (17.7%) close behind and no response to name lowest at 5.2%. Because no single red flag dominates, leaning on one familiar cue will miss others, which is why AAP separates ongoing surveillance from standardized screening and keeps caregiver history and clinical judgment across visits central rather than any one tool.
53.1% identify child psychology or mental health services as the allied health area with the most severe local shortage, while 26.0% choose universal funding and rapid early-intervention enrollment as the future innovation with the greatest impact.
Behavioral therapy or ABA is the next shortage at 33.3%, behind child psychology and mental health at 53.1%, while on the future question AI-assisted pre-visit screening (25.0%) sits almost level with universal funding and rapid enrollment (26.0%), ahead of expanded training (20.8%), EHR prompts (14.6%), and telehealth clinics (13.5%). The near-tie is the signal: respondents put an access reform and a workflow technology side by side, because better detection only helps if the child can actually enter services once the signal is found.
The survey describes a pathway where concerns surface early, standardized tools are familiar, and clinicians actively keep children moving while specialist capacity lags. The limiting points are distributed: consultation time, parental hope that waiting will be enough, referral delays, shortages in child psychology and behavioral services, and the work of connecting families to intervention before a definitive evaluation.
The core tension is timing. A child may first raise concern at 12 to 18 months, yet the same clinician works inside brief preventive visits and refers into a system where a developmental-behavioral or neurology appointment can take months, which makes early intervention, therapy access, parent communication, and primary-care follow-up part of the diagnostic pathway rather than something that begins after it.
You have read the summary
Direct answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
